CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers reported Monday.
The findings could lead to a new approval for the device, called Optune, beyond its current marketing clearance to treat a type of brain cancer. Delivering additional sales, however, could be a significant challenge.
Novocure’s study achieved its primary goal and showed a survival benefit for patients with lung cancer that progressed following initial chemotherapy. But those data don’t fit the current medical practice for patients with lung cancer because nearly 70% of study participants didn’t receive initial treatment with an immune checkpoint inhibitor such as Merck’s Keytruda, which has come to dominate current therapy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect